FDA Reports ‘Proliferation’ Of Cosmetics Making Drug Claims
This article was originally published in The Tan Sheet
Executive Summary
In a Consumer Update posted to its website, FDA suggests some cosmetic products “go too far” with their promises and urges consumers to be skeptical when faced with cosmetics making drug claims.
You may also be interested in...
Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.
FDA Remains Focused On Cosmetics Carrying Drug Claims – OCAC Director
At the American Conference Institute’s Legal, Regulatory and Compliance Forum on Cosmetics, FDA Office of Cosmetics and Colors Director Linda Katz discussed her division’s priorities for the year. On the enforcement front, OCAC will continue to focus on cosmetic products marketed with drug claims, she said.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.